Psychedelic-assisted Group Program for First Responders

Exclusion Criteria

• •Current or past history of schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), bipolar disorder, delusional disorder, dissociative disorder, paranoid personality disorder, schizoaffective disorder, borderline personality disorder, anorexia nervosa, bulimia nervosa or substance abuse, as assessed by medical history
• •Presence of active psychotic symptoms
• •Currently diagnosed psychotic disorder in first-degree relatives, not including psychotic disorders secondary to an apparent medical reason, e.g. brain injury, dementia, or lesions of the brain, as assessed by medical history.
• •Diagnosis of dementia or delirium
• •Risk of suicide as determined by the Investigator
• •Significantly intrusive PTSD as determined by the Investigator
• •Extreme emotional lability can be disruptive to the group milieu and is a relative exclusion criterion
• •Uncontrolled cardiopulmonary disease, cardiovascular disease, or hypertension
• •Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, vascular or any other major concurrent illness that, in the opinion of the Investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if he/she takes part in the study
• •Psychoactive substance use (MDMA, psilocybin, LSD) within the previous two months.
• •If female and of child-bearing potential: pregnant, suspected or planning to become pregnant during the study
• •Participation in another clinical trial (currently or within the last 30 days)
• •Current use of rifamycins (rifampin, rifabutin, rifapentine), anticonvulsants (carbamazepine, phenytoin, phenobarbital), nevirapine, efavirenz, taxol, dexamethasone); cytochrome P450 Inhibitors - including all HIV protease inhibitors, verapamil, diltiazem, itraconazole, ketoconazole, erythromycin, clarithromycin, azithromycin, and troleandomycin; ergot alkaloids, pimozide, midazolam, triazolam, lovastatin, simvastatin, fentanyl, warfarin, metoprolol, propranolol, buspirone, tramadol, selegiline, sumatriptan.
• •Current use of inhibitors of UGT1A9 and 1A10, monoamine oxidase inhibitors (MAOIs), Tricyclic antidepressants, aldehyde dehydrogenase inhibitors (ALDHs) and alcohol dehydrogenase inhibitors (ADHs).